Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2019. The document serves as a transaction notification regarding insider trading activity rather than a periodic financial report.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific securities transaction.
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053
- Transaction Type: Sale
- Volume: 25,000 ADSs
- Price: $45.3270 per ADS
- Transaction Date: November 29, 2019
- Exchange: New York Stock Exchange (XNYS)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a single transaction by a Person Discharging Managerial Responsibilities (PDMR).
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a statutory disclosure of a sale by Mr. B McNamara, CEO of GSK Consumer Healthcare.
Investor Verification Points
- Verify the total holdings of Mr. B McNamara following this sale of 25,000 ADSs.
- Confirm the market price of GSK ADSs on November 29, 2019, to validate the reported transaction price of $45.3270.
- Note that this filing does not reflect the company's overall financial results for the period; refer to Form 20-F for comprehensive financial data.